The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
Based on the Biotest Aktiengesellschaft stock forecast from 0 analysts, the average analyst target price for Biotest Aktiengesellschaft is not available over the next 12 months. Biotest Aktiengesellschaft’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Biotest Aktiengesellschaft is Neutral, which is based on 1 positive signals and 1 negative signals. At the last closing, Biotest Aktiengesellschaft’s stock price was USD 30.48. Biotest Aktiengesellschaft’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -11.91% over the last year.
No recent analyst target price found for Biotest Aktiengesellschaft
No recent average analyst rating found for Biotest Aktiengesellschaft
Company Overview Biotest Aktiengesellschaft
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for the treatment of haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; and Vihuma for treating haemophilia A acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect for prophylaxis of hepatitis B re-infection; Intratect for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; IgG Next Genration for primary immune deficiency and immunothrombocytopenia; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company's products under development include BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) to treat cytomegalovirus infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Tiancheng International Investment Limited. Read Less
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immuno...Read More
N/A
N/A
1,663
N/A
USD
USA
Adjusted Closing Price for Biotest Aktiengesellschaft (BIESF)
Loading...
Unadjusted Closing Price for Biotest Aktiengesellschaft (BIESF)
Loading...
Share Trading Volume for Biotest Aktiengesellschaft Shares
Loading...
Compare Performance of Biotest Aktiengesellschaft Shares
Symbol
Capital Gain
Dividend Return
Total Return
Loading...
Loading...
Technical Indicators for BIESF
Assets
Top Holdings
N/A
Top Sectors
Top Regions
Stocks Similar To Biotest Aktiengesellschaft (Sector: )
Frequently Asked Questions About Biotest Aktiengesellschaft (BIESF) Stock
Stock Target Advisor's fundamental analysis for Biotest Aktiengesellschaft's stock is Neutral.
Unfortunately we do not have enough data on BIESF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BIESF's stock to indicate what its average analyst target is.
BIESF stock's Price/Earning ratio is 5.50.
Based on this BIESF may be undervalued for its sector.
The last closing price of BIESF's stock was USD 30.48.
The most recent market capitalization for BIESF is USD 0.99B.
Unfortunately we do not have enough analyst data on BIESF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Biotest Aktiengesellschaft's stock.
As per our most recent records Biotest Aktiengesellschaft has 1,663 Employees.
Sorry we do not have any infomation available on Biotest Aktiengesellschaft's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Frequently Asked Questions About Biotest Aktiengesellschaft (BIESF) Stock
Stock Target Advisor's fundamental analysis for Biotest Aktiengesellschaft's stock is Neutral.
Unfortunately we do not have enough data on BIESF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BIESF's stock to indicate what its average analyst target is.
BIESF stock's Price/Earning ratio is 5.50.
Based on this BIESF may be undervalued for its sector.
The last closing price of BIESF's stock was USD 30.48.
The most recent market capitalization for BIESF is USD 0.99B.
Unfortunately we do not have enough analyst data on BIESF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Biotest Aktiengesellschaft's stock.
As per our most recent records Biotest Aktiengesellschaft has 1,663 Employees.
Sorry we do not have any infomation available on Biotest Aktiengesellschaft's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BIESF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
